European Organisation For Research & Treatment Of Cancer
LungTech: Stereotactic Body Radiotherapy (SBRT) of Inoperable Centrally Located NSCLC
- Conditions
- Non-small Cell Lung Cancer Stage IINon-small Cell Lung Cancer Stage I
- Interventions
- Radiation: Stereotactic Body Radiotherapy (SBRT)
- First Posted Date
- 2013-02-20
- Last Posted Date
- 2020-01-31
- Target Recruit Count
- 39
- Registration Number
- NCT01795521
- Locations
- 🇧🇪
Cliniques Universitaires Saint-Luc, Brussels, Belgium
🇩🇪Universitaetsklinikum Freiburg, Freiburg, Germany
🇩🇪Universitaetsklinikum Wuerzburg, Wuerzburg, Germany
Nintedanib(BIBF1120) in Thyroid Cancer
- Conditions
- Differentiated Thyroid Cancer (DTC)Medullary Thyroid Cancer (MTC)
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-02-11
- Last Posted Date
- 2020-07-31
- Target Recruit Count
- 100
- Registration Number
- NCT01788982
- Locations
- 🇧🇪
Cliniques Universitaires Saint-Luc, Brussels, Belgium
🇧🇪U.Z. Leuven - Campus Gasthuisberg, Leuven, Belgium
🇮🇹Azienda Ospedaliera Universitaria "Federico II", Napoli, Italy
Screening Platform for Clinical Trials in Advanced Colorectal Cancer
- Conditions
- Colorectal CancerAdvanced Colorectal Cancer
- Interventions
- Genetic: Tumour markers testing
- First Posted Date
- 2012-11-08
- Last Posted Date
- 2022-07-07
- Target Recruit Count
- 668
- Registration Number
- NCT01723969
- Locations
- 🇧🇪
Hopitaux Universitaires Bordet-Erasme - Hopital Universitaire Erasme, Brussels, Belgium
🇧🇪Cliniques Universitaires Saint-Luc, Brussels, Belgium
🇧🇪Universitair Ziekenhuis Antwerpen, Edegem, Belgium
TAK-700 in Castration Resistant Prostate Cancer
- Locations
- 🇧🇪
Cliniques Universitaires Saint-Luc, Brussels, Belgium
🇧🇪Onze Lieve Vrouw Ziekenhuis, Aals, Belgium
🇧🇪AZ Groeninge Kortrijk - Campus Vercruysselaan, Kortrijck, Belgium
Very Early FDG-PET/CT-response Adapted Therapy for Advanced Hodgkin Lymphoma (H11)
- Conditions
- Hodgkin Lymphoma
- Interventions
- Drug: ABVD + FDG-PET/CT Scan treatment adaptationDrug: BEACOPPesc
- Locations
- 🇩🇰
Rigshospitalet, Copenhagen, Denmark
Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases
- Conditions
- Liver MetastasesColorectal Cancer MetastaticKRAS Mutated Colorectal Cancer
- Interventions
- Drug: Modified FOLFOX6Procedure: SurgeryBiological: Aflibercept
Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1
- Conditions
- Elderly Metastatic Breast Cancer Population
- Interventions
- First Posted Date
- 2012-05-14
- Last Posted Date
- 2022-11-17
- Target Recruit Count
- 80
- Registration Number
- NCT01597414
- Locations
- 🇵🇹
Champalimaud Cancer Center, Lisboa, Portugal
🇫🇷Centre Paul Strauss, Strasbourg, France
🇳🇱VieCuri - Medisch Centrum voor Noord-Limburg - Locatie Venlo, Venlo, Netherlands
Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer
- Conditions
- Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastCirculating Tumor Cells
- Interventions
- First Posted Date
- 2012-03-08
- Last Posted Date
- 2019-03-13
- Target Recruit Count
- 1317
- Registration Number
- NCT01548677
- Locations
- 🇧🇪
Hôpitaux Universitaires Bordet-Erasme - Institut Jules Bordet, Brussels, Belgium
🇧🇪AZ Damiaan, Oostende, Belgium
🇧🇪C.H.U. Sart-Tilman, Liege, Belgium
Neoadjuvant Afatinib Window Study in Squamous Cell Carcinoma of the Head and Neck
- Conditions
- Carcinoma, Squamous Cell of Head and Neck
- Interventions
- Other: Observation
- First Posted Date
- 2012-02-24
- Last Posted Date
- 2018-07-09
- Target Recruit Count
- 30
- Registration Number
- NCT01538381
- Locations
- 🇮🇹
Istituto Nazionale Per Lo Studio E La Cura Dei Tumori, Milano, Italy
🇧🇪Institut Jules Bordet, Brussels, Belgium
🇧🇪Cliniques Universitaires St. Luc, Brussels, Belgium
CREATE: Cross-tumoral Phase 2 With Crizotinib
- Conditions
- Locally Advanced and/or Metastatic Anaplastic Large Cell LymphomaLocally Advanced and/or Metastatic Inflammatory Myofibroblastic TumorLocally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1Locally Advanced and/or Metastatic Alveolar Soft Part SarcomaLocally Advanced and/or Metastatic Clear Cell SarcomaLocally Advanced and/or Metastatic Alveolar Rhabdomyosarcoma
- Interventions
- First Posted Date
- 2012-02-02
- Last Posted Date
- 2023-12-11
- Target Recruit Count
- 582
- Registration Number
- NCT01524926
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
🇩🇪Medizinische Hochschule Hannover, Hannover, Germany
🇬🇧St. James's University Hospital, Leeds, United Kingdom